macro

Laurus Labs quarterly profit more than doubles and beats estimates

Laurus Labs posted strong September-quarter results, with net profit up 126.7% and revenue and EBITDA ahead of CNBC-TV18 poll estimates.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

Indian drugmaker Laurus Labs delivered a strong September-quarter report, according to TradingView. Net profit climbed 126.7% year on year to ₹442 crore in Q2 FY27 from ₹195 crore, comfortably above the ₹354.1 crore poll figure compiled by CNBC-TV18. Revenue rose 33.4% to ₹2,206 crore and EBITDA jumped 86% to ₹750 crore, lifting the margin to 34% from 24.4%. After the release, the stock traded 2.14% higher at ₹2,231.80 on the BSE.

The board also cleared the purchase of a 52% holding in SI & C Resins Private Limited, valued at ₹30 crore before the investment. Laurus will put in ₹32.5 crore, turning the polymer and silica maker into a subsidiary, and may add up to ₹30 crore more in its securities later. Separately, it agreed to take 60% of Canada's Galenvs Sciences Inc. at a $3.5 million pre-money valuation, investing $3.75 million in total, including $1 million bought from the founder.

An interim dividend of ₹1 per share on the ₹2 face value was approved, with November 6, 2026 as the record date and payment on or after November 19, 2026.

why it matters

For the market, the combination of profit and margin beating forecasts matters most, alongside acquisitions that widen the company's portfolio. Measured against revenue, the deal sizes look modest, so operating performance remains the main driver.

market impact

Laurus Labs shares: results above forecasts support the stock

  • Laurus Labs shares pressure up — profit and margin beat analyst estimates

tags

instruments

Laurus Labs sharesBSEIndian pharma stocksCAD/INR

sources

  1. Laurus Labs Q2 Results: Profit more than doubles, margin beats estimates; dividend declared — TradingView, 29 October 2026 at 09:50 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗